Navigation Links
Too much commitment may be unhealthy for relationships, UH psychology professor says
Date:12/2/2008

chology.

Collaborating with Knee were Amber L. Bush of UH, Amy Canevello of the University of Michigan and Astrid Cook of Idiro Technologies.

Included in these studies was a 14-day diary procedure in which 198 participants recorded the most positive and negative events in their romantic relationships.

Also documented in this daily diary were participants' feelings about themselves and their relationships.

"What we found with this particular study was that people with higher levels of RCSE felt worse about themselves during negative moments in their relationships," Knee said. "It's as if it doesn't matter why the negative occurrence happens or who was at fault. The partners with stronger RCSE still feel badly about themselves."

Individuals with RCSE also are prone to react more emotionally to relationship-based situations, Knee added. Instead of taking a step back, analyzing a situation and determining how to best address it, those with RCSE respond immediately and impulsively.

"When something happens in a relationship, these individuals don't separate themselves from it," he said. "They immediately feel personally connected to any negative circumstance in a relationship and become anxious, more depressed and hostile."


'/>"/>

Contact: Mike Emery
pemery@uh.edu
713-743-8186
University of Houston
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing
2. Saturn Shows Its Commitment to Health and Fitness by Becoming Expo Title Sponsor for The Detroit Free Press/Flagstar Marathon
3. AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence
4. Bill and Melinda Gates Call for New Global Commitment to Chart a Course for Malaria Eradication
5. Women Deliver Conference Launches New Commitments
6. Diverse Partners Renew Commitment to Reproductive Health, Rights in Asia
7. AMA Commends Aetna for Quality First Commitment
8. The American Diabetes Association Expands Commitment to Youth With Type 1 Diabetes
9. Malaria Community Applauds Clintons $1 Billion a Year Pledge; Invites Other Candidates to Make Malaria Commitments
10. Lung Cancer Alliance Praises Congressional Call for Increased Commitment to Fund Lung Cancer Research
11. Equal level of commitment and relationship satisfaction found among gay and heterosexual couples

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ption leads to success, study finds , ,...rcise, reduced soda consumption and self-weighing ...gies for adolescents, a new study shows. , Rese...t-control strategies and lifestyle habits. Sixty-t...The responses were grouped into four categories: ,...
(Date:12/4/2009)...patient groups , , FRIDAY, Dec. 4 (Healt... Ewing sarcomas and central nervous system tumors,...rs have found. , The study authors analyzed dat...on pediatric cancers who were enrolled in the Chil...found that the overall cancer recurrence rate was ...
(Date:12/4/2009)... to take breast cancer drug, study finds , ...out side effects are a major reason why only 6 per...cer are willing to take the drug tamoxifen to prev...ort to inform women about the risks and benefits o...igan Comprehensive Cancer Center created a decisio...
(Date:12/4/2009)...4 Today, seven of Florida,s top no...ng the health of Florida,s uninsured and underserv...2009 Sapphire Award ceremony. ,, The Sapphire A...izes and promotes organizations that have demonstr...ithin their communities. ,, Honorees of The 200...
(Date:12/4/2009)...re-FirstCall/ -- Movado Group Inc. (NYSE: MOV ),...a, Georgia, shared in a tribute on December 3, 200...ie Oudin for her stellar performance in the tourna...finalist at the Open since 1999. ,, (Photo: ...84 ) ,, At a celebratory reception held at Brow...
Breaking Medicine News(10 mins):Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
... May 20, 2009Physicians can and should play a lead...g towards comprehensive reform of the way health c...uaranteed 1.5 percent annual savings in health car...chieving Health Care ReformHow Physicians Can Help...
...al communities in California,s Central Valley , ,...re, one of the nation,s first and leading provider...of nephrology research, today announced their part...e Park in the City of Stockton. Satellite Healthca...
...ostatic intraepithelial neoplasia (HGPIN) carries ...ostate cancer. Research published in the open acce...atients whose extended core biopsy led to an initi...dation Trust and Lancaster University, along with ...
...hareholders to Support the Company,s Twelve Nomine..., Inc. (Nasdaq: AMLN ) today reminded its shareh...l of Amylin,s nominees, including its two new inde...bourne Capital Management, L.L.C. , , Amylin,s 20...
...., May 26 Cogdell Spencer Inc. (NYSE: CSA ) ann...lic offering of 18,000,000 shares of common stock....ters an option to purchase up to an additional 2,7...eds from the offering to fund a $50 million repaym...
...6 , , About Dr. Harold Kohn & Vimpat , A...l compound that affects neurological systems, Haro...hapel Hill , inventor of the recently FDA-approved... of perseverance, and Veronica was thrilled to tha...
Other Medicine News:Health News:Physicians can lead health care reform through payment and delivery system reforms 2Health News:Satellite Healthcare Walks for Kidney Health 2Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 2Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 3Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 4Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3Health News:Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug 2Health News:Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug 3
(Date:12/4/2009)... 4 Chemistry World re... Pharmaceutical Research and Manufacturers of Ame...accines in development for HIV/AIDS and related co...products in development include 23 vaccines and 54...cal trials or awaiting approval by the U.S. Food a...
(Date:12/4/2009)...wire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: ...ntermeasures against biological and chemical threa... results of a study demonstrating the effectivenes... in the New Zealand White (NZW) rabbit. The data ...HHS Public Health Emergency Medical Countermeasure...
(Date:12/4/2009)...4 OrthoAccel Technologies, Inc., d...acceleration device to enhance orthodontics, annou...n course published by PennWell Corporation , a le..., including medicine and dentistry. The course fo..., a summary of treatment biomechanics, factors tha...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4DURECT Corporation to Participate in Upcoming Healthcare Conferences 57474 1DURECT Corporation to Participate in Upcoming Healthcare Conferences 57474 2National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 1National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 2National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 1YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 4
... a First-in-Class Biologic Treatment Option Now Av...s with JIA(1,2) -, PRINCETON, N.J., April 8, 2008... announced that the U.S. Food and Drug,Administrat...reducing signs,and symptoms in pediatric patients ...tive polyarticular juvenile idiopathic arthritis (...
...d., April 8, 2008 ImQuest scientists Robert,W. Bu...nted the results of,studies performed with product...ecent Microbicides 2008, an international conferen...icide scientists, developers, and care,givers from...ak by the,Conference organizers, presenting the re...
Other Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India 2
Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD
Protein A 50 OD, Colloidal Gold Conjugated/Tagged
Protein A, Gold Ribbon - .25 OD per sq. cm.
Protein G, Gold Ribbon - .50 OD per sq. cm.
Medicine Products: